Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes

Diabetologia(2024)10.1007/s00125-024-06099-3Source: DataRank Database

Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes is a research paper published in Diabetologia (2024). On theSindex it has a DataRank of 0.546. It has been cited 37 times.

N/A

0.546DataRank · unranked

Scored on demand from live citation data

37 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)OA: hybridTopics (39)IDs (PubMed, PMC)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.546

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (18)

Katherine Young ORCID,Anand T. N. Nair,Rhian Hopkins ORCID,Andrew P. McGovern,Eram Haider

Live enrichment

PubMed:38388753 PMC:PMC10955037

British Heart Foundation

Grant: SP/19/6/34809

Medical Research Foundation

Grant: MR/N00633X/1

MICA: MRC APBI STratification and Extreme Response Mechanism IN Diabetes - MASTERMIND

National Institute for Health Research (NIHR)

Grant: ACF-2017-23-003

Medical Research Council

Grant: MR/K005707/1

Medical Research Council

Grant: MR/W003988/1

hybridLicense: CC BY

publisherhttps://link.springer.com/content/pdf/10.1007/s00125-024-06099-3.pdf

publisherhttps://link.springer.com/article/10.1007/s00125-024-06099-3/fulltext.html

Europe_PMChttps://europepmc.org/articles/PMC10955037

Europe_PMChttps://europepmc.org/articles/PMC10955037?pdf=render

https://doi.org/10.1007/s00125-024-06099-3

Fields of Study

03 medical and health sciences0302 clinical medicine

MeSH Terms

HumansDiabetes Mellitus, Type 2GlucoseHypoglycemic AgentsBayes TheoremPhenotypeFemaleMaleGlucagon-Like Peptide-1 ReceptorLiraglutideSodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor Agonists

Keywords

Type 2 diabetesPrecision MedicineSglt2-inhibitorsHeterogeneous Treatment EffectsGlp1-receptor AgonistsBayesian Non-parametric ModellingMale610name=Internal MedicineArticleGlucagon-Like Peptide-1 Receptor/dk/atira/pure/subjectarea/asjc/2700/2724HumansHypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsBayes TheoremLiraglutideDiabetes and MetabolismGlucosePhenotypeDiabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor Agonists/dk/atira/pure/subjectarea/asjc/2700/2712Femalename=Endocrinology

Sustainable Development Goals

SDG 3: 3. Good health

Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes

FAIR Checklist

DataRank Breakdown

Authors (18)

Funding (5 grants)

Open Access

Topics

Annotations (Europe PMC)